Carisma Therapeutics

Interested in a career at Carisma? Open positions are listed on our website or can be found through reputable recruiters. If you are looking for more information or are interested in open positions, please visit:

Biotech Careers | Cell Therapy Careers | Carisma Therapeutics Carisma Therapeutics is looking for passionate innovators to join a growing team, in the effort to advance CAR-Macrophage immunotherapy.

Looking forward to sharing the latest progress in our first-in-human Phase 1 clinical trial of CT-0508 at next weekend in Chicago. We are excited to be sharing additional patient data and our progress toward providing another therapeutic option for patients with hard-to-treat cancers. Click here for more information on our presence at ASCO and to hear the latest on Carisma’s commitment to innovation: https://carismatx.com/

Preliminary findings from our landmark clinical trial of CT-0508, a HER2-targeted CAR-Macrophage (CAR-M), were presented for the first time at today. The data showed that CT-0508 was well tolerated after infusion. It was also successfully manufactured using macrophages obtained from heavily pre-treated, advanced solid tumor patients. These findings also demonstrated that CT-0508 remodeled the solid tumor microenvironment and mediated expansion/activation of T cells within the tumors. Our clinical trial remains open for enrollment, and we look forward to furthering the investigation of the potential of CAR-Ms in hard-to-treat cancers.

Carisma Therapeutics Presents Data from Phase I Clinical Trial of CT-0508, A HER2 Targeted CAR-Macrophage /PRNewswire/ -- Carisma Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies,...

A late breaker abstract of clinical data from our landmark CT-0508 trial, as well as three pre-clinical study abstracts, have been accepted for an oral and three poster presentations at the upcoming . The oral presentation and posters will be available on the SITC website for registered attendees on November 12-13. https://www.prnewswire.com/news-releases/carisma-announces-multiple-abstracts-accepted-for-presentation-at-the-society-for-immunotherapy-of-cancer-36th-anniversary-annual-meeting-301411984.html

CARISMA Announces Multiple Abstracts Accepted for Presentation at The Society for Immunotherapy of Cancer 36th Anniversary Annual Meeting /PRNewswire/ -- CARISMA Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies,...

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to our lead candidate, CT-0508, an engineered macrophage designed for the treatment of solid tumors. The FDA’s Fast Track program is designed to facilitate the development and expedite the review of investigational treatments that demonstrate a potential to address unmet medical needs in serious conditions. This designation marks another important milestone in gene-based cell therapy development and reinforces the potential of this treatment for patients with hard-to-treat cancers. https://www.prnewswire.com/news-releases/carisma-therapeutics-announces-us-food-and-drug-administration-grants-fast-track-designation-to-ct-0508-for-the-treatment-of-patients-with-solid-tumors-301381843.html

We are excited to announce that Richard Morris has joined our leadership team as Chief Financial Officer, bringing more than 25 years of experience, to help further transform CARISMA as we progress as a clinical-stage company and beyond. Please join us in welcoming Richard to CARISMA! https://www.prnewswire.com/news-releases/carisma-therapeutics-appoints-richard-morris-as-chief-financial-officer-301307267.html?tc=eml_cleartime

We are CARISMA Therapeutics, a Philadelphia-based, clinical stage biopharmaceutical company that is pioneering the development of CAR macrophages, a disruptive and innovative approach to immunotherapy. Follow our page to receive updates about important company announcements and milestones and learn more about our exciting research and development, and our landmark clinical study evaluating engineered macrophages in humans. Visit our website for more information about CARISMA: https://carismatx.com/

Carisma Therapeutics | Solid Tumor Immunotherapy | CAR Macrophages Carisma Therapeutics is pioneering the development of CAR macrophages, a disruptive approach to immunotherapy to treat solid tumors.